This is a preview of subscription content, log in via an institution to check access.
References
Pharmaceutical Current Good Manufacturing Practices (cGMPs) for the 21st Century – A Risk Based Approach. US Food and Drug Administration Center for Drug Evaluation and Research. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/UCM071836.
WHO Expert Committee on Specifications for Pharmaceutical Preparations, WHO Technical Report Series No. 981. Geneva: World Health Organization; 2013. 202 p. 47th Report.
Harmonized Tripartite Guideline: Quality Risk Management, Q9. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2005. 19 p.
Implementation of risk management principles and activities within a Quality Management SystemGlobal Harmonization Task Force. 2005. 23 p.
ISO 14971: 2007. Medical devices - Application of risk management to medical devices. Geneva: International Organization for Standardization; 2007. 82 p.
Approved Risk Evaluation and Mitigation Strategies (REMS). US Food and Drug Administration; 2015. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed on 10 June 2015.
Viornery L, LeGoff P. Quality Risk Management: Implementation of ICH Q9 in the pharmaceutical field- an example of methodology from PIC/S. Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S). 2010. 30 p.
European Medicines Agency Benefit-risk methodology project. European Medicines Agency http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000314.jsp.
Structured Approach to Benefit-Risk Assessment in Drug Regulatory Decision-Making, Draft PDUFA V Implementation Plan. US Food and Drug Administration; 2013. 15 p. Available from: http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm326192.htm.
Guideline on good pharmacovigilance practices (GVP) Module V – Risk management systems (Rev 1). European Medicines Agency; 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf.
Smith MY, Morrato E. Advancing the Field of Pharmaceutical Risk Minimization Through Application of Implementation Science Best Practices. Drug Saf. 2014;37(8):569–80. doi:10.1007/s40264-014-0197-0. Published on-line 2014 Jul 9.
Guideline on plastic immediate packaging materials (CPMP/QWP/4359/03) and (EMEA/CVMP/205/04). European Medicines Agency; Committee for Medicinal Products for Human Use and the Committee for Medicinal Products for Veterinary Use. 2005. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003448.pdf.
Guidance for Industry. Container Closure Systems for Packaging Human Drugs and Biologics. Chemistry, Manufacturing and Controls Documentation. U.S. Food and Drug Administration Center for Drug Evaluation and Research; 1999. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070551.pdf.
Chapter <1663>, Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems, draft 2013. United States Pharmacopoeial Convention. Available from: http://www.usp.org/sites/default/files/usp_pdf/EN/meetings/workshops/m7126.pdf.
Chapter <1664>, Assessment of Drug Product Leachables Associated with Pharmaceutical Packaging Delivery Systems, draft 2013. United States Pharmacopoeial Convention. Available from: http://www.usp.org/sites/default/files/usp_pdf/EN/meetings/workshops/m7127.pdf.
Ball DJ, Norwood DL, Stults CLM, Nagao LM, editors. Leachables and extractables handbook: safety evaluation, qualification, and best practices applied to inhalation drug products. Hoboken: Wiley; 2012.
Safety Thresholds and Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products. Product Quality Research Institute; 2006. Available from: http://www.pqri.org/pdfs/LE_Recommendations_to_FDA_09-29-06.pdf.
Draft Guidance for Industry. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products. Chemistry Manufacturing and Controls Documentation. US Food and Drug Administration Center for Drug Evaluation and Research; 1998. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070573.pdf.
Tague NR. The Quality Toolbox. Milwaukee: American Society for Quality, Quality Press; 2005. p. 240.
Boven K et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney International. 2005;67:2346–53. doi:10.1111/j.1523-1755.2005.00340.x.
Design control guidance for medical device manufacturers. U.S. Food and Drug Administration Center for Device and Radiologic Health; 1997. Available from: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm070627.htm.
Council Directive 93/42/EEC of 14 June 1993 concerning medical devices, as amended by Directive 2007/47/EC of the European Parliament and of the Council. The European Parliament and the Council of the European Union.2007. Available from: http://www.emergogroup.com/sites/default/files/file/europe-consolidated-mdd-93-42-eec.pdf.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stults, C.L.M., Reckzuegel, G., Bailey, A. et al. Risk Management for Materials and Components Used in Orally Inhaled and Nasal Drug Products. Pharm Res 33, 1–17 (2016). https://doi.org/10.1007/s11095-015-1770-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-015-1770-7